{"id":"NCT02608476","sponsor":"Cassiopea SpA","briefTitle":"A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (26)","officialTitle":"A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 Weeks in Subjects With Facial Acne Vulgaris","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-11-16","primaryCompletion":"2018-02-21","completion":"2018-02-21","firstPosted":"2015-11-18","resultsPosted":"2020-11-20","lastUpdate":"2020-11-20"},"enrollment":732,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Acne Vulgaris"],"interventions":[{"type":"DRUG","name":"CB-03-01 cream, 1%","otherNames":["cortexolone 17α-propionate","clascoterone (USAN, INN)"]},{"type":"DRUG","name":"Vehicle cream","otherNames":[]}],"arms":[{"label":"CB-03-01 cream","type":"EXPERIMENTAL"},{"label":"Vehicle cream","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of this study is to determine the safety and efficacy of CB-03-01 cream, 1%, versus the vehicle cream applied twice daily for 12 weeks in subjects with facial acne vulgaris.","primaryOutcome":{"measure":"Percentage of Participants Achieving Success in Investigator's Global Assessment (IGA)","timeFrame":"Week 12","effectByArm":[{"arm":"CB-03-01 Cream","deltaMin":20.3,"sd":null},{"arm":"Vehicle Cream","deltaMin":6.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"9 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":52,"countries":["United States","Bulgaria","Georgia","Poland","Romania","Serbia"]},"refs":{"pmids":["36745367","34607697","32320027"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":369},"commonTop":["Nasopharyngitis","Rhinorrhoea","Oropharyngeal pain","Headache","Upper respiratory tract infection"]}}